CagriSema is an investigational, once-weekly subcutaneous co-formulation that pairs cagrilintide, a long-acting amylin analog, with semaglutide, a GLP-1 receptor agonist. The bottom line the published record supports is a real one: the combination has produced greater average weight loss than semaglutide alone in trials, yet it remains unapproved for any indication, and its flagship phase 3 result landed below the loftiest market expectations.
CagriSema is an investigational fixed-dose combination of cagrilintide and semaglutide that produced greater average weight loss than semaglutide alone in trials but is not approved for any indication.
CagriSema is not a new chemical entity but two established peptide drugs held in one syringe at a fixed ratio. One component is an amylin analog and the other a GLP-1 receptor agonist, and only the second reaches the market on its own today.
| Component | Cagrilintide | Semaglutide |
|---|---|---|
| Drug class | Long-acting amylin analog (dual amylin and calcitonin receptor agonist) | GLP-1 receptor agonist |
| Native hormone mimicked | Amylin, co-secreted with insulin | GLP-1 incretin hormone |
| Standalone approval | Investigational, not approved | Approved for type 2 diabetes and chronic weight management |
CagriSema fixes cagrilintide, an investigational amylin analog, and semaglutide, an approved GLP-1 receptor agonist, at a set ratio in a single once-weekly injection, so the two doses cannot be titrated fully independently.
Appetite runs on overlapping hormonal circuits rather than a single switch, and each drug engages a different one. That separation is the mechanistic argument for the pairing, since recruiting a second pathway can reinforce satiety in a way that pushing one receptor harder cannot.
Semaglutide acts on GLP-1 receptors while cagrilintide acts on amylin and calcitonin receptors, so CagriSema engages two partly separate satiety circuits rather than intensifying a single mechanism.
Across its trial program the combination has generally produced larger average weight reductions than semaglutide alone, but the margin is narrower than a dramatic doubling. The incremental gain has often landed in the low-to-mid single digits of percentage points, which is part of why interpretation has been contentious.
| Population | Combination | Semaglutide alone |
|---|---|---|
| Obesity without diabetes | Mid-teens to low-20s percent over about 12 to 16 months | Low-to-mid teens at standard dose |
| Type 2 diabetes | Blunted absolute loss versus non-diabetic cohorts | Also blunted, a class-wide pattern |
| Gain over semaglutide | Low-to-mid single-digit percentage points | Reference standard |
In obesity populations without diabetes the combination has driven mean weight loss of roughly the mid-teens to low-20s percent over about a year to sixteen months, an incremental gain over semaglutide typically measured in low-to-mid single-digit percentage points.
Tolerability is dominated by gastrointestinal effects, an expected consequence of two agents that both slow gastric emptying and act on nausea-related brainstem circuitry. The reported symptom load is real, though the trial data suggest it runs broadly in line with high-dose incretin therapy rather than dramatically worse.
Gastrointestinal effects, led by nausea, dominate the combination's side-effect profile and cluster during dose escalation, with adverse-event discontinuation generally reported in the single-digit to low-double-digit percent range.
The flagship phase 3 obesity trial shows how a clinically strong result can still land as a disappointment. The headline weight loss was large by any historical standard, yet it fell short of the loftiest projections, and a flexible titration design that left many participants below the top dose muddied how the average should be read.
The flagship trial's mean weight loss reached the low-20s percent on the completer view and closer to the high-teens on the conservative estimand, but a flexible titration design left many participants below the maximum dose, blurring whether the average reflected a true efficacy ceiling or an under-dosing artifact.
The co-formulation is investigational and not approved for any indication in any major market, a distinction the sheer volume of coverage can obscure. Development sits in late phase 3, and until an approval issues, any legitimate clinical use is confined to trials.
CagriSema is investigational and not approved for any indication in any major market, sits in late phase 3 development, and cannot be legitimately prescribed or obtained outside a clinical trial.
Administration follows the pattern of long-acting injectable obesity therapy: a single once-weekly subcutaneous injection, typically into the abdomen, thigh, or upper arm. Because the product is a fixed-dose co-formulation, the amylin analog and the GLP-1 agonist rise together at a set ratio rather than being tuned separately.
The combination is given as a single once-weekly subcutaneous injection begun at a low dose and escalated over several weeks, with the fixed-dose ratio raising the amylin analog and GLP-1 agonist together rather than independently.
Obesity is the headline indication, but the program reaches further because both components carry metabolic actions. The record shows active study in type 2 diabetes and expected effects on obesity-related comorbidities, though none of these secondary uses is established or approved.
Beyond obesity, the combination is being studied in type 2 diabetes for glycemic control and is expected to affect obesity-related comorbidities such as hypertension, sleep apnea, and fatty liver disease, though none of these secondary uses is established or approved.
Educational use only. This article describes what the published scientific and clinical literature reports about CagriSema. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
